Banner laxative petition denied
This article was originally published in The Tan Sheet
Executive Summary
Data presented by Banner Pharmacaps fails to show docusate calcium can be interchanged with docusate sodium, FDA says in a Nov. 17 letter. The firm asked in a 2002 petition that the two ingredients be considered interchangeable in OTC laxative drug product monograph combinations. (1"The Tan Sheet" June 24, 2002, In Brief). The agency says data are needed showing the bioavailability of docusate calcium relative to docusate sodium "is not affected when combined with sennosides A and B or sodium carboxymethylcellulose." The letter recommends firm contact the agency's OTC division before commencing new studies...
You may also be interested in...
Cyanotech
Nasdaq sends Cyanotech delisting warning letter June 18 for "failure to comply with the $1 minimum bid price." Company has until Sept. 16 to regain compliance. Also, FDA acknowledges receipt of May 28 joint letter from firm and Earthrise Nutritionals asking agency to stop evaluating ingredient spirulina as being GRAS for use in bars, powdered nutritional drink mixes while firms "clarify and prepare additional information for a new notice." Cyanotech and Earthrise jointly had submitted a GRAS petition for spirulina microalgae March 21 (1"The Tan Sheet" April 22, 2002, In Brief)...
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.